Abstract / Description of output
INTRODUCTION: People immobilized following acute spontaneous intracerebral haemorrhage (ICH) are at risk of venous thromboembolism (VTE) but the role of short-term prophylactic anticoagulation remains uncertain. We surveyed UK clinical practice and opinion regarding preventing VTE after ICH.
PATIENTS AND METHODS: An online survey was sent to stroke healthcare professionals within the United Kingdom and Ireland via a professional society (British and Irish Association of Stroke Physicians (BIASP)).
RESULTS: One hundred and twenty-three staff members responded to the survey, of whom 80% were consultant stroke physicians. All responders except one considered the issue to be important or extremely important, but only 5 (4%) were "extremely certain" and 51 (41%) "fairly certain" regarding the optimal treatment approach. Intermittent pneumatic compression (IPC) devices alone were the most used method (in 60%) followed by IPC devices and switching to low molecular weight heparin (LMWH) (in 30%). We identified high levels of uncertainty regarding the role of anticoagulation, and its optimal timing; uncertainty was greater in lobar compared to deep ICH. Most respondents (93%) consider a randomised controlled trial investigating the role of pharmacological VTE prophylaxis after acute ICH as important and would consider participation.
DISCUSSION AND CONCLUSION: The optimal method for the prevention of VTE in non-traumatic ICH patients remains an area of clinical uncertainty. Clinical trials assessing short-term anticoagulation in patients after acute ICH would be beneficial in providing evidence to resolve this clinical dilemma.
Original language | English |
---|---|
Pages (from-to) | 120855 |
Journal | Journal of the Neurological Sciences |
Volume | 454 |
Early online date | 23 Oct 2023 |
DOIs | |
Publication status | Published - 25 Oct 2023 |
Keywords / Materials (for Non-textual outputs)
- Humans
- Anticoagulants/therapeutic use
- Cerebral Hemorrhage/therapy
- Clinical Decision-Making
- Heparin, Low-Molecular-Weight/therapeutic use
- Stroke/drug therapy
- Surveys and Questionnaires
- Uncertainty
- Venous Thromboembolism/complications